Research
Our research focuses the dissection of mechanisms that underlie response and resistance to immunotherapies and on the longitudinal tracking of tumor cell evolution using single-cell lineage-tracing approaches based on interrogation of natural barcodes like somatic nuclear or mitochondrial DNA mutations.
Highlighted
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
Blood
·
13 Apr 2023
·
doi:10.1182/blood.2022018246
Single cell RNA sequencing analysis dissecting responses to ipilimumab treatment of relapsed AML/MDS with and without stem cell transplantation.
All
Showing 7 of 34 results
Clear search
Clear search
2025
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer
Journal of Hematology & Oncology
·
14 Feb 2025
·
doi:10.1186/s13045-025-01669-3
NK cell therapy in combination with CTLA-4 blockade for head and neck cancer
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy
Science Immunology
·
24 Jan 2025
·
doi:10.1126/sciimmunol.adr0782
Tracking determinants of response to donor lymphocyte infusion in AML and CML
2024
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia
Leukemia
·
26 Aug 2024
·
doi:10.1038/s41375-024-02381-w
Immune cell networks in pediatric and adult acute myeloid leukemia
Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice
Journal of Clinical Investigation
·
25 Jun 2024
·
doi:10.1172/JCI177460
TIM-3 inhibition stimulates graft-versus-leukemia responses against AML
2023
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer
Science Immunology
·
29 Sep 2023
·
doi:10.1126/sciimmunol.adf4968
First demonstration that preexisting tumor-resident T cells associate with response to neoadjuvant anti-PD-1 in head and neck cancer
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
Blood
·
13 Apr 2023
·
doi:10.1182/blood.2022018246
Single cell RNA sequencing analysis dissecting responses to ipilimumab treatment of relapsed AML/MDS with and without stem cell transplantation.